Enanta Pharmaceuticals: Pay

Enanta Pharmaceuticals paid its 2 named executives $4.1M in total in FY2025 (Sep). CEO Jay R. Luly, Ph.D. was paid $2.8M of that.

Pay$100 in the stock at the end of FY20 → $26
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Jay R. Luly, Ph.D.President and Chief Executive Officer
FY2025 (Sep)Not disclosed
FY2024 (Sep)
FY2023 (Sep)
FY2022 (Sep)Not disclosed
FY2021 (Sep)Not disclosed
5 years
Yat Sun Or, Ph.D.Chief Scientific Officer
FY2022 (Sep)Not disclosed
FY2021 (Sep)Not disclosed
2 years
Scott T. Rottinghaus, M.D.Chief Medical Officer
FY2025 (Sep)Not disclosed
FY2024 (Sep)
FY2023 (Sep)Not disclosed
FY2022 (Sep)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Sep), the median CEO pay of the 10 peers with pay on file was $4.0M. The CEO of Enanta Pharmaceuticals was paid $2.8M, 31% below the median.

  1. 1Travere Therapeutics
  2. 2Altimmune
  3. 3Nektar Therapeutics
  4. 4Rigel Pharmaceuticals
  5. 5Regenxbio
  6. 6Vanda Pharmaceuticals
  7. 7Lexicon Pharmaceuticals
  8. 8Enanta Pharmaceuticals
  9. 9Editas Medicine
  10. 10Inovio Pharmaceuticals
  11. 11Arbutus Biopharma
  12. 12Allogene TherapeuticsNot disclosed
  13. 13Arcturus Therapeutics HoldingsNot disclosed
  14. 14Heron TherapeuticsNot disclosed
  15. 15Karyopharm TherapeuticsNot disclosed
  16. 16MacrogenicsNot disclosed
  17. 17OmerosNot disclosed
  18. 18Puma BiotechnologyNot disclosed
  19. 19Sage TherapeuticsNot disclosed
  20. 20Sangamo PharmaceuticalsNot disclosed
  21. 21Sutro BiopharmaNot disclosed
  22. 22Theravance BiopharmaNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.